3CDC. Annual Causes of Death in the United States [ EB/OL]. (2014-08-25) [ 2014-10-10 ]. http://www, drugwarfacts, org/ cms/Causes of Death#sthash. mrhoo6zv. 8rRkOVlo. dpbs.
6Fang H, Su Z, Wang Y, et al. Exploring the FDA Adverse Event Reporting System to Generate Hypotheses for Monitoring of Disease Characteristics[J]. Clin Pharmacol Ther, 2014, 95(5) : 496-498.
7Edwards IR, Aronson JK. Adverse drug reactions : definitions, di- agnosis, and management [J].Lancet, 2000, 356 (9237) : 1255- 1259.
2Shi S, Klotz U. Drug interactions with herbal medicines [ J ]. Clin Pharmavokinet, 2012, 51 ( 2 ) : 77 -104.
3Shi S, Li Y. Interplay of drug-metabolizing enzymes and transporters in drug absorption and disposition [ J ]. Curr Drug Metab,2014, 15 (10) :915-941.
5Kim T, Jancel T, Kumar P, et al. Drug-drag interaction between isa- vuconasole and tacrolimus: a case report indicating the need for ta- crolimus drug-level monitoring [J]. J Clin Pharm Ther. 2015,40 (5) :609-611.
6Shl S, Klotz U. Age-related changes in pharmacokinetics [J]. Curr Drug Metab, 2011, 12(7) :601-610.
7Shi S, Mtirike K, Klotz U. The clinical implications of ageing for ra- tional drug therapy [ J ]. Eur J Clin Pharmacol, 2008, 64 (2) :183- 199.
8Shi S. Biologics: an update and challenge of their pharmacokinetics [J]. Curt Drug Metab, 2014,15(3) :271-290.
9Huttner A, Harbarth S, Hope WW, et al. Therapeutic drug monito- ring of the β-lactam antibiotics : what is the evidence and which pa- tients should we be using it for? [J]. JAntimicrob Chemother,2015, 70(12) :3178-3183.
10Mandrioli R, Protti M, Mercolini L. Novel atypical antipsychotics: metabolism and therapeutic drug monitoring (TDM) [ J]. Curr Drug Metab, 2015, 16(2) :141-151.
